Autolus Therapeutics (AUTL) EPS (Weighted Average and Diluted) (2020 - 2025)
Autolus Therapeutics posted quarterly EPS (Weighted Average and Diluted) of -$0.34 for Q4 2025, down 277.78% year-on-year from $0.19 in Q4 2024, and down 13.33% on a QoQ basis from -$0.3 in Q3 2025.
Autolus Therapeutics (AUTL) has 6 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.34 in Q4 2025.
- For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) fell 277.78% year-over-year to -$0.34; the trailing twelve-month figure through Dec 2025 stood at -$1.08 (down 25.58% YoY), and the FY2025 full-year result was -$1.08, down 25.58% from the prior year.
- EPS (Weighted Average and Diluted) for Q4 2025 stood at -$0.34, down from -$0.3 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at $0.53 in Q1 2021 and bottomed at -$3.43 in Q4 2021.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.26 (2023), against an average of -$0.33.
- The widest annual swing landed in 2021, when EPS (Weighted Average and Diluted) surged 100.0%; it then sank 277.78% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$3.43 in 2021, then surged by 93.29% to -$0.23 in 2022, then plunged by 95.65% to -$0.45 in 2023, then jumped by 80.0% to -$0.09 in 2024, then tumbled by 277.78% to -$0.34 in 2025.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.34 (Q4 2025), -$0.3 (Q3 2025), and -$0.18 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 4.02 |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 6.75 |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 1.51 |
| 10 | Autolus Therapeutics | - | - | -1.04 Mn | -0.34 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.34 |
| Sep 30, 2025 | -0.30 |
| Jun 30, 2025 | -0.18 |
| Mar 31, 2025 | -0.26 |
| Dec 31, 2024 | -0.09 |
| Sep 30, 2024 | -0.31 |
| Jun 30, 2024 | -0.22 |
| Mar 31, 2024 | -0.24 |
| Dec 31, 2023 | -0.45 |
| Sep 30, 2023 | -0.26 |
| Jun 30, 2023 | -0.26 |
| Mar 31, 2023 | -0.23 |
| Dec 31, 2022 | -0.23 |
| Sep 30, 2022 | -0.47 |
| Jun 30, 2022 | -0.46 |
| Mar 31, 2022 | -0.41 |
| Dec 31, 2021 | -3.43 |
| Sep 30, 2021 | 0.47 |
| Jun 30, 2021 | 0.47 |
| Mar 31, 2021 | 0.53 |
| Sep 30, 2020 | -19,334.20 |
| Jun 30, 2020 | -26,266.39 |